Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.
Moore NF, et al. Among authors: drake le.
Oncotarget. 2014 Sep 30;5(18):8737-49. doi: 10.18632/oncotarget.2372.
Oncotarget. 2014.
PMID: 25228590
Free PMC article.